Article Type
Changed
Mon, 01/07/2019 - 13:06

 

The application of transcranial direct-current stimulation and spinal cord stimulation alleviated freezing of gait in two separate studies of patients with idiopathic Parkinson’s disease published online in Movement Disorders.

SOURCES: Dagan M et al. Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300; Samotus O et al. Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.

Publications
Topics
Sections

 

The application of transcranial direct-current stimulation and spinal cord stimulation alleviated freezing of gait in two separate studies of patients with idiopathic Parkinson’s disease published online in Movement Disorders.

SOURCES: Dagan M et al. Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300; Samotus O et al. Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.

 

The application of transcranial direct-current stimulation and spinal cord stimulation alleviated freezing of gait in two separate studies of patients with idiopathic Parkinson’s disease published online in Movement Disorders.

SOURCES: Dagan M et al. Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300; Samotus O et al. Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.

Publications
Publications
Topics
Article Type
Click for Credit Status
Ready
Sections
Article Source

FROM MOVEMENT DISORDERS

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Vitals

 

Key clinical point: Transcranial direct-current stimulation (tDCS) shows promise for treating freezing of gait in Parkinson’s disease patients.

Major finding: Freezing of gait–provoking test scores improved in 15 of 17 patients who received simultaneous tDCS to the primary motor cortex and the left dorsolateral prefrontal cortex.

Study details: A double-blind, randomized trial of tDCS in 20 Parkinson’s disease patients and a nonrandomized, open-label study of spinal cord stimulation in 5 Parkinson’s patients.

Disclosures: The tDCS trial was supported by the Michael J. Fox Foundation for Parkinson’s Research. One investigator disclosed that he is cofounder and shareholder of Neuroelectrics, which makes brain stimulation technologies such as the ones used in the study. No outside funding was reported for the SCS study. One investigator in the SCS study reported ties to pharmaceutical companies and device manufacturers.

Sources: Dagan M et al. Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300; Samotus O et al. Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.

Disqus Comments
Default